Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation...

Related Keywords

United States ,Massachusetts ,Cambridge ,Cambridgeshire ,United Kingdom ,American ,Peter Kelleher ,Greg Dearborn ,Adam Silverstein ,Karin Hellsvik ,Adrian Gottschalk ,B Degrader Program ,Key Recent Program Updates ,American Association For Cancer Research ,Exchange Commission ,Linkedin ,Twitter ,Degrader Program ,Therapeutics Inc ,Nasdaq ,Foghorn Therapeutics Inc ,Development Expenses ,Company Annual Report On Form ,Gene Traffic Control ,Chief Executive Officer ,Cancer Research ,Annual Meeting ,Chromatin Regulation ,Chromatin Regulation Summit ,Kristian Humer ,Chief Financial ,Recent Program Updates ,Kinase Inhibitor ,Cancer Cell ,Cash Equivalents ,Gene Traffic ,Annual Report ,Consolidated Statements ,Months Ended March ,Foghorn Therapeutics ,Lifesci Advisors ,Markets ,